MorningSignal
Research Platform
2026-09-28 13:40
date: 2026-08-13 session: PM status: PROVISIONAL_RELEASE_ONLY tags: [earnings, sellside, tif]
Backlink: [[Daily/2026-08-13]]
| Company | Tier | File status | Print/reaction | Decision | Next proof point |
|---|---|---|---|---|---|
| [[AMAT]] | 1 | PROVISIONAL — RELEASE ONLY | Broad operating beat; shares about $507.69 at 19:59 ET, roughly 5% below the pre-print close | WAIT | Complete call; Q4 revenue at least $9.75B and non-GAAP EPS at least $3.82 |
| [[BAP]] | 1 | PROVISIONAL — CALL NOT YET HELD | 20.3% ROE and strong loan/deposit growth; shares about $375 | WAIT | Aug. 14 call; quantify 22% ROE bridge and El Niño reserve cases |
| [[BLTE]] | 1 | PROVISIONAL — TRANSCRIPT PENDING | Priority Review is intact; accounting EPS flattered by interest income; shares about $166.95 | WAIT | Complete call, February 12, 2027 PDUFA, launch economics |
| [[CELC]] | 1 | PROVISIONAL — TRANSCRIPT PENDING | Approval de-risks science but the commercial model is unproved; shares about $88.35 | WAIT | Complete call, first shipments, payer access, sNDA acceptance |
| [[DLO]] | 3 | DEFERRED to 2026-08-14 | Primary payment-volume/take-rate package incomplete | NO ACTION | Complete primary schedules and calls |
| [[HTFL]] | 3 | DEFERRED to 2026-08-14 | Specialist operating and reimbursement package incomplete | NO ACTION | Complete primary schedules and calls |
| [[NKTR]] | 3 | DEFERRED to 2026-08-14 | Specialist clinical and runway package incomplete | NO ACTION | Complete primary data and calls |
| [[STNE]] | 3 | DEFERRED to 2026-08-14 | TPV, take-rate and credit bridge incomplete | NO ACTION | Complete primary schedules and calls |
| [[HAWK]] | 3 | DEFERRED to 2026-08-14 | Contract, backlog and constellation economics incomplete | NO ACTION | Complete primary schedules and calls |
The deterministic calendar also returned nine greater-than-$2B rows whose session could not be resolved responsibly: NU, KB, QXO, DDS, VIPS, CIG, SKE, LPL and HUBG. They are excluded from PM coverage rather than silently forced into the wrong session.
Three different expectation problems matter tonight. AMAT delivered the best operating print, but the stock reaction says a premium multiple already discounted an unusually strong memory and advanced-packaging cycle. BAP delivered a high-return bank print, yet the next estimate delta depends on whether its 22% medium-term ROE ambition survives El Niño provisioning and Yape credit normalization. BLTE and CELC are both biotech transition stories: regulatory progress is real, but the equity values already capitalize commercialization outcomes that have not been demonstrated. In every case the backward-looking beat is less important than the unverified forward bridge.
The broad read-through is constructive for wafer-fab-equipment demand and Peruvian credit growth, but much less informative for near-term stock selection. AMAT's DRAM mix, leading-edge logic and service growth support the equipment cycle, while its after-hours decline warns that “AI exposure” without a fresh upside surprise is insufficient at more than 30 times an annualized guided quarter. BAP's low-cost deposit growth and declining NPL ratio are positive for Peruvian financial conditions, but the quarter also shows how weather-related reserves can overwhelm otherwise improving risk metrics. In biotech, an accepted NDA or approved drug moves technical probability, not automatically commercial value; payer access, label breadth, launch execution and cash burn remain the causal KPIs.
Status: PROVISIONAL — RELEASE ONLY. A complete, speaker-attributed transcript and full Q&A were not available by the cutoff. Webcast availability and third-party highlights do not satisfy the call gate. Sentiment record: [[EarningsSentiment/Companies/AMAT]].
The prior company guide set Q3 revenue at $8.95B ± $0.50B, non-GAAP EPS at $3.36 ± $0.20, Semiconductor Systems near $6.9B, Applied Global Services near $1.75B, and non-GAAP gross margin near 50.1%. Public preview work from Hudson Labs placed revenue expectations near $9.0B; a decision-grade buy-side hurdle was not publicly verifiable. TIF's Analytical Ledger contained no open AMAT threshold. The valuation-implied bar was much higher than the accounting consensus: at the approximately $534.54 pre-print close, annualizing the $4.02 Q4 EPS midpoint implied roughly 33.2x, requiring sustained double-digit equipment growth and continued margin expansion rather than a one-quarter beat.
AMAT cleared the operational bar. Q3 revenue was $9.115B, up 25% YoY and about 1.8% above the guide midpoint. Non-GAAP EPS was $3.50, up 41% YoY, while GAAP EPS was $3.17. Non-GAAP gross margin reached 50.4%, up 150 basis points YoY and roughly 40 basis points sequentially; non-GAAP operating margin was 34.0%, up 310 basis points YoY and about 190 basis points sequentially. Semiconductor Systems revenue was $7.040B, with 55.3% gross margin and 37.7% operating margin; AGS revenue was $1.781B, with 35.6% gross margin and 30.1% operating margin. The result beat is therefore principally operating, not an obvious tax artifact. The quality caveat moves to Q4: the $4.02 ± $0.20 non-GAAP EPS guide includes about $0.06 of intra-entity and stock-compensation tax benefits, so a normalized midpoint is closer to $3.96.
Semiconductor Systems accelerated because leading-edge foundry/logic, DRAM and advanced packaging are all using more process steps and more sophisticated materials engineering. Revenue mix was 67% foundry/logic, 26% DRAM and 7% NAND. DRAM is the conspicuous rate-of-change driver: more gate-all-around, high-bandwidth-memory and advanced-packaging complexity increases deposition, etch, metrology and packaging intensity per wafer. AGS grew about 22% YoY, which improves revenue durability because service, spares and productivity software monetize the installed base rather than only new-fab construction. The causal chain is stronger device complexity → more critical materials steps → higher systems content → a larger installed base → more service revenue.
There are two buried cautions. First, China fell to 28% of revenue from 35%, while the United States rose to 15%; diversification helps sanctions risk, but it also means the next leg must come from expensive leading-edge capacity rather than mature-node China demand. Second, accounts receivable increased to $7.691B from $5.185B and inventory to $6.564B from $5.915B. Cash from operations was still a strong $3.037B and free cash flow about $2.330B, but the working-capital build makes one quarter of cash conversion a poor annualization base. The compound beat flag is positive—revenue, margin and EPS all improved—but the stock's move to roughly $507.69 after hours, about 5% below the pre-print close, shows that the expectations beat was smaller than the valuation hurdle.
The Q4 guide is revenue $10.25B ± $0.50B and non-GAAP EPS $4.02 ± $0.20. At the midpoint, revenue rises about 12.5% sequentially and the annualized EPS run rate is $16.08. At $507.69, that is still approximately 31.6x. Bull: AI compute, HBM, advanced packaging and leading-edge logic sustain 20%-plus systems growth, AGS compounds near double digits, gross margin remains above 50%, and the premium multiple is earned. Base: systems growth moderates into the mid-teens in calendar 2027, AGS remains resilient, margin holds around 50%, and multiple compression offsets EPS growth. Bear: memory capex or advanced-packaging orders pause, export controls pressure China, receivables/inventory convert slowly, and a sub-30x multiple overwhelms earnings growth.
The business delta is positive: breadth and margin are better than the prior quarter. The estimate delta is also positive because Q4 midpoint revenue and EPS are above the Q3 run rate, though six cents of Q4 EPS is tax-assisted. The stock delta is negative because valuation demanded a larger surprise. Old narrative: AMAT is an AI and memory-capex beneficiary with improving service mix. New narrative: the operating thesis is working, but the stock requires continuous upward revisions and cannot tolerate merely strong delivery. Bull claim: process complexity structurally raises equipment intensity. Bear rebuttal: cycle and customer concentration still govern order timing. Bull response: AGS and multi-node exposure reduce, but do not eliminate, cyclicality.
Action: WAIT. A valuation entry is $460 or lower—about 28.6x the annualized Q4 EPS midpoint—or proof that Q4 revenue is at least $9.75B, EPS at least $3.82, and gross margin remains at or above 50%. Confirmation is a complete call showing calendar-2027 growth is capacity- and customer-backed rather than double ordering. Falsification is Q4 revenue below $9.75B, gross margin below 49.8%, or a calendar-2027 systems-growth outlook below the mid-teens.
Call questions held open: What portion of calendar-2027 demand is backed by customer cleanroom capacity and non-cancellable schedules? How much of Q4 growth is DRAM versus advanced packaging, and what does that mix do to gross margin? Why did receivables and inventory rise so sharply, and when should working capital normalize? What is the downside case if China restrictions tighten? How much of the Q4 EPS step-up is operating after removing the $0.06 tax benefit?
Status: PROVISIONAL — CALL NOT YET HELD. The company scheduled its Q2 call for August 14 at 10:30 ET; prepared remarks and Q&A therefore did not exist at the PM cutoff. Sentiment record: [[EarningsSentiment/Companies/BAP]].
The prior guide centered on approximately 19.5% 2026 ROE, with sensitivity to El Niño. Public calendar discovery indicated an EPS hurdle near $7.20, but the currency translation and provider definition make that a lower-confidence comparison; no verified buy-side hurdle or open TIF Ledger threshold was available. The pre-print valuation bar was already substantive. At about $375, annualizing Q2 net income per share and translating at roughly 3.4 soles per dollar produces an earnings run rate near $29 per share, or roughly 13x. Book value is approximately $141 per share on the same FX convention, implying about 2.7x book. That multiple needs a sustainable 20%-plus ROE, not only a benign credit quarter.
Q2 net income was S/1.982B, up 8.8% YoY and down 3.9% sequentially, equal to S/25.0 per share. ROE reached 20.3%. Loans grew 13.1% YoY and 4.3% sequentially; on a currency-neutral basis, growth was 14.6% and 5.2%. Deposits grew 17.7% YoY, with low-cost deposits up 25.1% and representing 74.4% of total deposits. Net interest income increased 13.3% YoY, and net interest margin expanded to 6.63%, up 21 basis points YoY and 5 basis points sequentially. The NPL ratio improved 91 basis points YoY and 22 basis points sequentially to 4.1%.
The headline quality is good but not clean. Provisions increased 27.1% YoY and 51.7% sequentially, including S/106M of El Niño provisions, equal to 27 basis points of cost of risk. Reported cost of risk was 1.9%; underlying cost of risk excluding that charge was 1.6%. Risk-adjusted NIM was 5.5%, or 5.7% on the underlying convention. This is not a simple credit normalization story: better delinquencies and funding coexist with a weather reserve that could recur or prove insufficient.
Credicorp's engine is the spread between loan yield and a deposit base increasingly funded by low-cost balances, less expected credit loss and operating expense. Q2 improved all three major numerator inputs—loan volume, NIM and fee-like income. Other core income rose 19.7% YoY and represented 26.8% of risk-adjusted revenue. The main digital driver is Yape: 16.7M monthly active users, 69 monthly transactions per user, revenue per user of S/11.1 versus expense per user of S/6.0, and contribution equal to 8.9% of risk-adjusted revenue. Yape loans reached S/1.817B, up 309% YoY. That growth is economically meaningful: engagement creates payment revenue and a proprietary underwriting funnel, but fast unsecured-credit seasoning can reverse quickly.
Efficiency was 45.6% for the first half, 26 basis points worse YoY, as operating expense rose 13.5% year to date and innovation expense 33.1%. Insurance underwriting results fell 17.9% YoY. Those are the buried offsets to banking strength. Capital remains adequate—BCP CET1 was 11.7% and Mibanco 15.9%—but the investment case hinges on converting innovation spending into durable fee and credit economics without letting loss ratios rise. Management reaffirmed the roughly 19.5% 2026 ROE guide with upside bias and raised its medium-term ambition to approximately 22%. The rate-of-change question is whether that increase is a real structural bridge from mix, Yape and efficiency, or a top-down aspiration exposed to reserve and FX volatility.
Base case: loan growth normalizes toward low double digits, NIM remains above 6.4%, underlying cost of risk holds near 1.6%-1.8%, and ROE settles around 20%-21%. Bull: low-cost deposits and Yape monetization keep revenue growth above expense growth, El Niño provisions prove conservative, and ROE reaches 22%, supporting the current premium to book. Bear: weather and consumer stress lift cost of risk above 2%, Yape vintages season poorly, insurance remains weak, and the efficiency ratio fails to improve; book-value growth then matters more than the aspirational ROE.
The business delta is positive because funding mix, NIM, loan growth and asset quality all improved. The estimate delta is modestly positive, but the unquantified El Niño range prevents a clean FY1/FY2 revision. The stock delta is neutral: a roughly 0.8% regular-session gain does not imply that the market accepted the new 22% target. Old narrative: Credicorp is normalizing back toward high-teens ROE as Peruvian credit and digital adoption improve. New narrative: 20% ROE is delivered and 22% is plausible, but Yape credit and climate reserves are now the proof points. Bull claim: the low-cost deposit mix makes the ROE uplift structural. Bear rebuttal: provisions and operating investment absorb the funding benefit. Bull response: underlying risk-adjusted NIM and Yape unit economics show enough cushion if credit remains controlled.
Action: WAIT. The valuation trigger is $340 or lower, approximately 11.5x the annualized translated earnings run rate, or a call that quantitatively bridges 22% ROE with underlying cost of risk no higher than 1.7%. Confirmation requires 2026 ROE at least 19.5%, low-cost deposits above 73%, and Yape credit losses remaining within the disclosed risk appetite. Falsification is cost of risk above 2.1%, NIM below 6.3%, or a retreat from the 19.5% ROE guide.
Call questions held open: How many basis points of the move from 19.5% to 22% ROE come from NIM, fees, efficiency, credit and capital? What are the El Niño base, upside and downside reserve cases? What are Yape loan vintages, delinquency and risk-adjusted margins? When does innovation spending peak, and what efficiency ratio is embedded in FY2? Why did insurance underwriting deteriorate, and is the pressure transitory?
Status: PROVISIONAL — TRANSCRIPT PENDING. The 16:30 ET call occurred, but no complete speaker-attributed transcript with full Q&A was available. Sentiment record: [[EarningsSentiment/Companies/BLTE]].
BLTE is pre-revenue, so the useful pre-print stack is regulatory and cash based rather than revenue-consensus based. The verified hurdle was FDA acceptance of the tinlarebant NDA for Stargardt disease, Priority Review, and a February 12, 2027 PDUFA date. Public calendar EPS consensus was approximately -$0.78; no decision-grade buy-side hurdle or open TIF Ledger call was available. The valuation-implied bar is demanding: cash plus Treasury securities were approximately $780M against a market capitalization near $7.0B, leaving roughly $6.2B of enterprise value. At a 4x-6x mature sales multiple, that capitalizes about $1.0B-$1.6B of risk-adjusted peak revenue before launch evidence.
The quarter did not alter the core clinical event. The 104-subject DRAGON pivotal trial remained complete; at month 25, quantitative autofluorescence lesion growth was approximately stable to down 2% in treated patients versus up around 20% on placebo. DRAGON II enrolled 73 subjects, including 15 Japanese patients. PHOENIX enrolled 530 patients in geographic atrophy. The company plans a September Commercial Day. Those are meaningful development and readiness milestones, but none supplies price, label breadth, payer access, patient identification or launch velocity.
GAAP net loss widened to $28.4M from $16.3M, and GAAP loss per share to $0.70 from $0.50. Non-GAAP loss was $21.6M, or $0.54 per share. R&D increased to $18.2M from $11.0M, while SG&A increased to $16.7M from $6.5M as commercialization work accelerated. Interest and other income was $6.6M, up from $1.3M. That below-line income equals roughly $0.16 per share on the quarter's share count, more than the apparent $0.08 GAAP EPS beat versus the public calendar estimate. The “beat” is therefore low quality for the investment thesis; operating spending and regulatory probability matter more. Weighted shares increased about 23% YoY, making dilution another part of per-share value.
The operating engine has four sequential gates: approval and label; retinal-specialist identification of eligible patients; payer coverage and prior authorization; and persistence on therapy. DRAGON addresses the first by showing a slower lesion-growth mechanism, but the economic value depends on how the FDA translates that endpoint into the label and how payers value a chronic therapy for a rare progressive disease. SG&A's increase is consistent with launch preparation, yet without a quantified sales-force footprint, pricing assumption and gross-to-net range, investors cannot distinguish prudent readiness from premature fixed cost.
Cash and Treasuries were about $780M, modestly above the prior year-end balance because financing and interest obscure operating burn. Sequentially, the balance declined by roughly $19M from the prior quarter's disclosed level. The runway is therefore not the immediate risk; value destruction can come from paying a full commercial multiple before approval and access are proved. An algebraic sensitivity makes the bar visible. At $6.2B enterprise value and a 5x peak-sales multiple, the equity implies approximately $1.24B of risk-adjusted peak sales. At a 60% approval-and-commercial-success probability, required un-risked peak sales are about $2.1B. This is not a forecast; it is the revenue scale embedded in the current price under explicit assumptions.
Bull: Priority Review, a differentiated mechanism and clinically meaningful slowing establish a rare-disease franchise, approval occurs on time, and launch economics support multi-billion-dollar peak sales. Base: approval occurs, but payer adoption and diagnosis ramp slowly; spending rises ahead of revenue and the current valuation leaves modest upside. Bear: label restrictions, a complete response letter, monitoring burden or slow access reduce the addressable market; the multiple compresses before revenue can validate it. The business delta is positive because Priority Review is secured. The estimate delta is negative on operating loss but economically secondary. The stock delta is negative—shares were about $166.95, with a roughly 7% regular-session decline—because regulatory progress was already embedded.
Old narrative: pivotal efficacy and NDA filing offer a near-term de-risking path. New narrative: FDA review is active, but commercial proof—not cash runway—is the marginal question. Bull claim: Priority Review materially raises time value and probability. Bear rebuttal: acceptance is not approval, and the enterprise value already assumes a large franchise. Bull response: DRAGON differentiation can justify premium pricing if label and payer coverage are broad.
Action: WAIT. Require $145 or lower plus no deterioration in the regulatory path, or wait through approval and the first quantified payer-access framework. Confirmation is approval by February 12, 2027 with a commercially usable label, no onerous monitoring burden, and a credible path to at least $1.2B risk-adjusted peak sales. Falsification is a complete response letter, a materially restricted label, launch delay beyond mid-2027, or annualized cash use above $150M before revenue.
Call questions held open: What exact label, safety-monitoring and manufacturing risks remain? What patient pool, price and gross-to-net assumptions support the launch plan? How many retina specialists and diagnosed patients can be activated in year one? When is the PHOENIX interim analysis and what would be decision-relevant? How much SG&A and working capital are required through the first full launch year?
Status: PROVISIONAL — TRANSCRIPT PENDING. A complete speaker-attributed transcript and full Q&A were not available by the cutoff. Sentiment record: [[EarningsSentiment/Companies/CELC]].
The decisive prior hurdle was no longer approval probability: the FDA approved REVTORPYK on July 14 for HR-positive/HER2-negative, PIK3CA-wild-type advanced or metastatic breast cancer after endocrine therapy. The company expects shipments late in Q3, and NCCN lists the regimen as a preferred Category 1 option. Public consensus focused on adjusted loss near $1.08 per share; no verified buy-side hurdle or open Ledger threshold was available. The valuation bar is commercial. Market capitalization was about $4.5B and cash plus investments approximately $754M, but convertible notes were also roughly $753M, leaving enterprise value near the equity value. At 4x-6x mature sales, the price embeds approximately $0.75B-$1.12B of risk-adjusted peak revenue.
The efficacy package is strong. In PIK3CA-mutant VIKTORIA-1, the triplet produced a 0.50 hazard ratio and 11.1 months median PFS versus 5.6 months for the control; the doublet produced a 0.51 hazard ratio and 11.3 months versus 5.6 months. Objective response rates were 49% and 36%, and discontinuation for adverse events was 5.2% and 3.8%, versus 19.1% for the alpelisib comparator. The company intends an sNDA in Q3 and has expanded first-line VIKTORIA-2. Science and regulatory breadth are improving simultaneously.
The financial variance is mostly launch investment. There was no product revenue in Q2. GAAP loss widened to $78.9M, or $1.44 per share, from $45.3M, or $1.04. Non-GAAP loss was $58.7M, or $1.07 per share. Operating expense rose to $66.1M from $44.0M. R&D fell to $31.1M from $36.4M, but SG&A rose to $35.0M from $7.6M; approximately $23.4M of the increase related to launch headcount and activities. Operating cash use was $55.4M, up from $36.2M. The adjusted EPS comparison is not a valuation beat: roughly $20M of non-cash and financing-related items separates GAAP from non-GAAP loss, while cash burn is accelerating.
The commercial engine starts with eligible post-endocrine patients, oncologist awareness and NCCN positioning, then flows through payer coverage, prior authorization, gross-to-net, duration and combinations. The Category 1 preferred status helps demand formation, while the adverse-event discontinuation profile can be a practical differentiator against PI3K-pathway alternatives. But the release supplies none of the first-quarter launch KPIs—covered lives, formulary position, patient starts, refill persistence, channel inventory or gross-to-net. Late-Q3 shipments may create distributor inventory before true end-demand, so early revenue must be reconciled to patient starts.
Financing reduced near-term liquidity risk but introduced a buried per-share issue. Celcuity raised about $557M net from convertible notes and used $137M to repay its loan. Cash and investments fund operations into 2029, but the notes approximate the cash balance and can dilute the upside. The investment case therefore cannot treat $754M as unencumbered net cash. At roughly $4.5B enterprise value and a 5x sales multiple, the stock implies about $900M of risk-adjusted peak sales. At a 70% probability of commercial execution, that becomes about $1.3B un-risked peak sales. Again, this is an explicit valuation sensitivity, not a sales forecast.
Bull: strong PFS, tolerability, NCCN status and label expansion make gedatolisib a backbone therapy; access builds quickly and the first-line program expands duration and market size. Base: approval produces a credible launch, but gross-to-net and patient identification delay the ramp while SG&A remains elevated. Bear: payer management, combination complexity or safety monitoring slow adoption; channel inventory masks weak patient starts, and convert dilution limits per-share upside. The business delta is strongly positive because approval and NCCN positioning remove major technical risk. The estimate delta is negative near term as commercial cost rises before revenue. The stock delta is negative—about $88.35 late, following a roughly 6% regular-session decline—because the market now demands launch evidence.
Old narrative: pivotal data and FDA review determine survival. New narrative: approval is secured; payer access, patient starts and cash-efficient commercialization determine value. Bull claim: the 50% reduction in progression risk and lower discontinuation create real differentiation. Bear rebuttal: the approved population and post-endocrine setting may be narrower than headline trial efficacy suggests. Bull response: the PIK3CA-mutant sNDA and first-line work create credible label-expansion options, but those options should not be fully capitalized today.
Action: WAIT. Require $70 or lower—where the implied risk-adjusted peak-sales bar falls materially—or initial launch evidence showing at least 60% covered lives, clean patient-start growth and gross-to-net no worse than 20%. Confirmation is on-time late-Q3 shipments, sNDA acceptance, and early prescriptions that are not merely channel inventory. Falsification is a launch delay into 2027, gross-to-net worse than 25%, quarterly operating cash use above $75M without matching demand evidence, or a safety/label issue that impairs duration.
Call questions held open: What are list price, gross-to-net and payer-access assumptions? How many covered lives and patient starts are expected by year-end? What channel inventory will precede recognized revenue? What is the sNDA acceptance and decision timeline? How should investors model launch SG&A, cash use and convert dilution through 2027?
The same-day AM report was already finalized after complete calls rather than left provisional, so there is no unsupported “release-only” conclusion to reverse. Full-session evidence confirmed the AM decisions: [[TPR]] remains WAIT at $118 or Q1 proof; [[CLBT]] remains WAIT at $9.50 or Q3 ARR proof; [[JD]] remains WAIT at $27 or Q3 retail-growth proof. Late prices of about $129.60, $10.84 and $29.34 respectively do not cross those entry thresholds. The settled interpretation is unchanged: TPR has durable Coach strength but decelerating expectations, CLBT has real timing recovery but weaker forecast credibility, and JD has better gross-margin mechanics but needs top-line and investment-budget proof. Source: [[EarningsBrief/EarningsBrief_2026-08-13_AM]].
/Users/max/morningsignal-research/state/earnings/earnings_context_2026-08-13_PM.jsonPENDING_TRANSCRIPT.[[Daily/2026-08-13|Back to the daily note]]